In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- Is This the AI Endgame? What Happens to GI?
- The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb
- Medicare to cover colorectal cancer screenings ordered by PAs, APRNs (Becker’s GI & Endoscopy)
- America Is Running Out of Doctors (The Health Care Blog)
- Weighed Down by Paperwork: Identifying Barriers to Metabolic and Bariatric Surgery Evaluation in the United States (Springer Nature)
- Banning Corporate Medicine: Stopping Private Equity’s Debt Trap (Forbes)
- Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal (The New England Journal of Medicine)
- Blood test targets ‘Achilles’ heel’ of CRC screening, detects 81% of advanced adenomas (Healio)
